Luis J V Galietta
Overview
Explore the profile of Luis J V Galietta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
129
Citations
4760
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guidone D, De Santis M, Pesce E, Capurro V, Pedemonte N, Galietta L
J Physiol
. 2025 Mar;
PMID: 40047394
Electrogenic transepithelial ion transport can be measured with the short-circuit current technique. Such experiments are frequently used to evaluate the activity of the cystic fibrosis transmembrane conductance regulator (CFTR), a...
2.
Tomati V, Capurro V, Pesce E, Pastorino C, Sondo E, Lena M, et al.
Front Pharmacol
. 2024 Dec;
15:1494327.
PMID: 39624835
Introduction: Cystic Fibrosis (CF) is a genetic disease due to loss-of-function mutations of the CFTR channel. F508del is the most frequent mutation (70% of alleles in Italy), while other mutations...
3.
Pagani I, Venturini A, Capurro V, Nonis A, Ghezzi S, Lena M, et al.
Am J Respir Cell Mol Biol
. 2024 Sep;
72(3):308-319.
PMID: 39311876
The coronavirus disease (COVID-19) pandemic has underscored the impact of viral infections on individuals with cystic fibrosis (CF). Initial observations suggested lower COVID-19 rates among CF populations; however, subsequent clinical...
4.
Barreca M, Renda M, Spano V, Montalbano A, Raimondi M, Giuffrida S, et al.
Eur J Med Chem
. 2024 Aug;
276:116691.
PMID: 39089001
Although substantial advances have been obtained in the pharmacological treatment of cystic fibrosis (CF) with the approval of Kaftrio, a combination of two correctors (VX-661, VX-445) and one potentiator (VX-770),...
5.
Esposito A, Rossi A, Stabile M, Pinto G, De Fino I, Melessike M, et al.
ACS Pharmacol Transl Sci
. 2024 Jun;
7(6):1807-1822.
PMID: 38898954
Over the past few years, l-iminosugars have revealed attractive pharmacological properties for managing rare diseases including Cystic Fibrosis (CF). The iminosugar -butyl-l-deoxynojirimycin (l-NBDNJ, -), prepared by a carbohydrate-based route, was...
6.
Genovese M, Galietta L
Cell Calcium
. 2024 May;
121:102905.
PMID: 38788257
TMEM16 proteins, also known as anoctamins, are a family of ten membrane proteins with various tissue expression and subcellular localization. TMEM16A (anoctamin 1) is a plasma membrane protein that acts...
7.
Mazio C, Scognamiglio L, Casale C, Panzetta V, Urciuolo F, Galietta L, et al.
Biomaterials
. 2024 Mar;
308:122546.
PMID: 38552367
Patients with cystic fibrosis (CF) experience severe lung disease, including persistent infections, inflammation, and irreversible fibrotic remodeling of the airways. Although therapy with transmembrane conductance regulator (CFTR) protein modulators reached...
8.
Ciciriello F, Panariello F, Medino P, Biffi A, Alghisi F, Rosazza C, et al.
J Cyst Fibros
. 2024 Mar;
23(4):625-632.
PMID: 38508950
Background: People with cystic fibrosis (pwCF) are considered at risk of developing severe forms of respiratory viral infections. We studied the consequences of COVID-19 and virus-host cell interactions in CF...
9.
Zajac M, Lepissier A, Dreano E, Chevalier B, Hatton A, Kelly-Aubert M, et al.
Front Pharmacol
. 2023 Dec;
14:1293578.
PMID: 38149052
Cystic fibrosis (CF) is caused by defective Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) proteins. CFTR controls chloride (Cl) and bicarbonate (HCO ) transport into the Airway Surface Liquid (ASL). We...
10.
Novel tricyclic pyrrolo-quinolines as pharmacological correctors of the mutant CFTR chloride channel
Renda M, Barreca M, Borrelli A, Spano V, Montalbano A, Raimondi M, et al.
Sci Rep
. 2023 May;
13(1):7604.
PMID: 37165082
F508del, the most frequent mutation in cystic fibrosis (CF), impairs the stability and folding of the CFTR chloride channel, thus resulting in intracellular retention and CFTR degradation. The F508del defect...